Opko Health (OPK) Issues Earnings Results, Beats Estimates By $0.03 EPS

Share on StockTwits

Opko Health (NASDAQ:OPK) posted its quarterly earnings results on Friday. The biotechnology company reported ($0.05) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.03, Briefing.com reports. Opko Health had a negative return on equity of 9.32% and a negative net margin of 31.73%. The company had revenue of $250.00 million for the quarter, compared to analysts’ expectations of $264.04 million. During the same period in the previous year, the firm earned ($0.08) EPS. The firm’s revenue was up 1.6% compared to the same quarter last year.

Shares of OPK traded down $0.40 during mid-day trading on Friday, hitting $3.09. 7,341,070 shares of the stock were exchanged, compared to its average volume of 3,831,201. The stock has a market capitalization of $2.16 billion, a price-to-earnings ratio of -10.66 and a beta of 1.89. Opko Health has a 52-week low of $2.66 and a 52-week high of $6.40. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.05 and a quick ratio of 0.90.

In other news, CEO Phillip Md Et Al Frost acquired 5,000 shares of the firm’s stock in a transaction dated Tuesday, August 28th. The shares were acquired at an average cost of $5.80 per share, with a total value of $29,000.00. Following the acquisition, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at $17,799,915.80. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders have bought a total of 70,000 shares of company stock worth $392,950 over the last ninety days. Insiders own 42.74% of the company’s stock.

OPK has been the topic of a number of research analyst reports. Barrington Research reissued a “buy” rating and issued a $7.00 price target on shares of Opko Health in a report on Friday, October 5th. BidaskClub cut Opko Health from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 8th. Cantor Fitzgerald reissued a “buy” rating and issued a $20.00 price target on shares of Opko Health in a report on Tuesday, August 7th. Finally, ValuEngine raised Opko Health from a “sell” rating to a “hold” rating in a report on Thursday, July 26th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. Opko Health has an average rating of “Hold” and an average price target of $9.69.

COPYRIGHT VIOLATION NOTICE: This article was originally published by Ticker Report and is the property of of Ticker Report. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this article can be read at https://www.tickerreport.com/banking-finance/3929145/opko-health-opk-issues-earnings-results-beats-estimates-by-0-03-eps.html.

About Opko Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.

Featured Story: Swap

Earnings History for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Opko Health  Issues  Earnings Results, Beats Estimates By $0.03 EPS
Opko Health Issues Earnings Results, Beats Estimates By $0.03 EPS
Omeros  Releases  Earnings Results, Misses Estimates By $0.04 EPS
Omeros Releases Earnings Results, Misses Estimates By $0.04 EPS
Informa’s  Buy Rating Reaffirmed at Shore Capital
Informa’s Buy Rating Reaffirmed at Shore Capital
Premier African Minerals’  “Speculative Buy” Rating Reaffirmed at Northland Securities
Premier African Minerals’ “Speculative Buy” Rating Reaffirmed at Northland Securities
Vodafone Group’s  Underperform Rating Reaffirmed at Macquarie
Vodafone Group’s Underperform Rating Reaffirmed at Macquarie
Allianz  PT Set at €210.00 by Barclays
Allianz PT Set at €210.00 by Barclays


Leave a Reply

© 2006-2018 Ticker Report